Contact – +1-276-477-5910
 Email – [email protected]

Home >>

Healthcare and Social Assistance

>>

Business Opportunities and Investment Strategies for Global Respiratory Drugs Market


Business Opportunities and Investment Strategies for Global Respiratory Drugs Market 2023-2033

Report code: SDMRGM1703190 | Industry: Healthcare and Social Assistance | Published On: 2024-06-07


Opportunity and Strategy Analysis
This report focuses on identifying opportunities and strategies for investing in the global respiratory drugs market within the forecast period. It provides a complete analysis of the global market both quantitatively and qualitatively. The quantitative analysis includes market size and revenue data of the total demand, sub-markets, and regional/national levels throughout 2023-2033. Qualitative analysis depicts a full picture of market dynamics and trends including drivers, restraints and challenges, emerging products/market trends, and Porter’s Fiver Forces analysis.

Based on the market data and analysis, the report highlights Increasingly Attractive Segments (IAS) and business opportunities in each segmentation. Moreover, a systematic evaluation of Internal Risks (factors arising within the industry development) and External Risks (factors arising from the surrounding environments) is provided for the respiratory drugs industry and market. All the identified risk factors are measured quantitatively according to GMD’s novel numeric system, i.e. each risk is evaluated with GMD Risk Index Number (GMD RIN) and GMD Risk Intensity Level (GMD RIL). This in-depth risk assessment offers a comprehensive understanding of the current risk factors and their developing trends. Furthermore, this report concludes risk management strategies and Critical Success Factors (CSFs) to help companies make intelligence-based business decisions in the global respiratory drugs industry.

Market Coverage & Overview
The report is based on studies for 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. Considering impact of COVID-19 and regional conflicts such as Russia-Ukraine war, the trend and outlook of global market is forecast in optimistic, balanced, and conservative scenarios. In the balanced view, the global respiratory drugs market is expected to reach $203.4 billion by 2033, growing by 6.6% annually over the coming years.

Segmentation Analysis
Highlighted with 90 tables and 104 figures, this 189-page report represents a 360-degree view on the global market with extensively detailed segmentations Drug Type, Disease, Drug Composition, Formulation, Administration, Distribution Channel, and Region/Country as shown below. Annual revenue 2023-2033 for each segment is included in the report.

By Drug Type
• Anti-Asthmatics & COPD Drugs
• Cough & Cold Preparations
• Pulmonary Hypertension Drugs
• Idiopathic Pulmonary Fibrosis Drugs
• Other Drug Types

By Disease
• Asthma
• COPD
• Allergic Rhinitis
• Cystic Fibrosis
• Pulmonary Hypertension
• Idiopathic Pulmonary Fibrosis
• Other Respiratory Diseases

By Drug Composition
• Stand Alone Drugs
• Combination Drugs

By Formulation
• Dry Powder
• Tablets & Capsules
• Sprays
• Syrups & Solutions

By Administration
• Inhalational Drugs
• Oral Drugs
• Injection Drugs

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa, and Rest of MEA)
The breakdown of all regional markets by country and the breakdown of each national market by Drug Type, Formulation, and Distribution Channel over the forecast years are also included.

Key Companies
The report also covers the current competitive scenario and profiles key vendors including market leaders and important emerging players. A selection of companies profiled in this report includes:
• Abbott Laboratories
• AstraZenca PLC
• Boehringer Ingelheim GmbH
• Bristol Myers Squibb Company
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Vertex Pharmaceuticals Inc.

1  Introduction 10
1.1  Industry  Definition  and  Research  Scope 10
1.1.1  Industry  Definition 10
1.1.2  Research  Scope 11
1.2  Research  Methodology 14
1.2.1  Overview  of  Market  Research  Methodology 14
1.2.2  Market  Assumption 15
1.2.3  Secondary  Data 15
1.2.4  Primary  Data 15
1.2.5  Data  Filtration  and  Model  Design 16
1.2.6  Market  Size/Share  Estimation 17
1.2.7  Research  Limitations 18
1.3  Executive  Summary 19
2  Market  Overview  and  Dynamics 22
2.1  Market  Size  and  Forecast 22
2.1.1  Impact  of  COVID-19  on  World  Economy 23
2.1.2  Impact  of  COVID-19  on  the  Market 27
2.1.3  Impact  of  Russia-Ukraine  Conflict 29
2.1.4  Impact  of  Israel-Palestine  War 31
2.2  Major  Growth  Drivers 32
2.3  Market  Restraints  and  Challenges 37
2.4  Emerging  Opportunities  and  Market  Trends 40
2.5  Porter’s  Fiver  Forces  Analysis 43
3  Segmentation  of  Global  Market  by  Drug  Type 47
3.1  Market  Overview  by  Drug  Type 47
3.2  Anti-Asthmatics  &  COPD  Drugs 50
3.3  Cough  &  Cold  Preparations 51
3.4  Pulmonary  Hypertension  Drugs 52
3.5  Idiopathic  Pulmonary  Fibrosis  Drugs 53
3.6  Other  Drug  Types 54
4  Segmentation  of  Global  Market  by  Disease 55
4.1  Market  Overview  by  Disease 55
4.2  Asthma 58
4.3  COPD 59
4.4  Allergic  Rhinitis 60
4.5  Cystic  Fibrosis 61
4.6  Pulmonary  Hypertension 62
4.7  Idiopathic  Pulmonary  Fibrosis 63
4.8  Other  Respiratory  Diseases 64
5  Segmentation  of  Global  Market  by  Drug  Composition 65
5.1  Market  Overview  by  Drug  Composition 65
5.2  Stand  Alone  Drugs 68
5.3  Combination  Drugs 69
6  Segmentation  of  Global  Market  by  Formulation 71
6.1  Market  Overview  by  Formulation 71
6.2  Dry  Powder 74
6.3  Tablets  &  Capsules 75
6.4  Sprays 76
6.5  Syrups  &  Solutions 77
7  Segmentation  of  Global  Market  by  Administration 78
7.1  Market  Overview  by  Administration 78
7.2  Inhalational  Drugs 81
7.3  Oral  Drugs 82
7.4  Injection  Drugs 83
8  Segmentation  of  Global  Market  by  Distribution  Channel 84
8.1  Market  Overview  by  Distribution  Channel 84
8.2  Hospital  Pharmacies 87
8.3  Retail  Pharmacies 88
8.4  Online  Pharmacies 89
9  Segmentation  of  Global  Market  by  Region 90
9.1  Geographic  Market  Overview  2023-2033 90
9.2  North  America  Market  2023-2033  by  Country 95
9.2.1  Overview  of  North  America  Market 95
9.2.2  U.S. 99
9.2.3  Canada 102
9.2.4  Mexico 104
9.3  European  Market  2023-2033  by  Country 106
9.3.1  Overview  of  European  Market 106
9.3.2  Germany 110
9.3.3  U.K. 112
9.3.4  France 114
9.3.5  Spain 116
9.3.6  Italy 118
9.3.7  Russia 120
9.3.8  Rest  of  European  Market 122
9.4  Asia-Pacific  Market  2023-2033  by  Country 124
9.4.1  Overview  of  Asia-Pacific  Market 124
9.4.2  Japan 128
9.4.3  China 131
9.4.4  Australia 133
9.4.5  India 135
9.4.6  South  Korea 137
9.4.7  Rest  of  APAC  Region 139
9.5  South  America  Market  2023-2033  by  Country 141
9.5.1  Argentina 145
9.5.2  Brazil 147
9.5.3  Chile 149
9.5.4  Rest  of  South  America  Market 151
9.6  MEA  Market  2023-2033  by  Country 152
9.6.1  UAE 156
9.6.2  Saudi  Arabia 158
9.6.3  South  Africa 160
9.6.4  Other  National  Markets 162
10  Competitive  Landscape 163
10.1  Overview  of  Key  Vendors 163
10.2  New  Product  Launch,  Partnership,  Investment,  and  M&A 166
10.3  Company  Profiles 167
Abbott  Laboratories 167
AstraZenca  PLC 169
Boehringer  Ingelheim  GmbH 170
Bristol  Myers  Squibb  Company 171
F.  Hoffmann  La  Roche  Ltd. 172
GlaxoSmithKline  Plc 173
Merck  &  Co.  Inc. 174
Novartis  AG 175
Pfizer  Inc. 176
Sanofi 177
Teva  Pharmaceutical  Industries  Ltd. 178
Vertex  Pharmaceuticals  Inc. 179
11  Investing  in  Respiratory  Drugs  Industry:  Risk  Assessment  and  Management 180
11.1  Risk  Evaluation  of  Global  Market 180
11.2  Critical  Success  Factors  (CSFs) 186
RELATED  REPORTS 189
To know more, kindly contact [email protected]
 Feel free to contact us

 
Choose License Type
Select User Type


Report code




x

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT